Test Code BAPS Bile Acid Profile, Serum
Ordering Guidance
This test is intended for use by research scientists. Approval must be obtained before ordering.
Specimen Required
Patient Preparation: Patient must be fasting for 12 to 14 hours.
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Useful For
Evaluating the enterohepatic cycle consisting of the biliary system, intestine, portal circulation, and hepatocytes
Supporting researchers in need of free and conjugated values of all 20 bile acid species as well as total bile acid
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Reporting Name
Bile Acid Profile, SSpecimen Type
SerumSpecimen Minimum Volume
0.3 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 90 days | |
Ambient | 90 days | ||
Frozen | 90 days |
Reject Due To
Gross hemolysis | OK |
Gross lipemia | OK |
Clinical Information
Bile acids are formed in the liver from cholesterol, conjugated primarily to glycine and taurine, stored and concentrated in the gallbladder, and secreted into the intestine after the ingestion of a meal. In the intestinal lumen, the bile acids serve to emulsify ingested fats and thereby promote digestion. During the absorptive phase of digestion, approximately 90% of the bile acids are reabsorbed.
The efficiency of the hepatic clearance of bile acids from portal blood maintains serum concentrations at low levels in normal persons. An elevated fasting level, due to impaired hepatic clearance, is a sensitive indicator of liver disease. Following meals, serum bile acid levels have been shown to increase only slightly in normal persons, but markedly in patients with various liver diseases, including cirrhosis, hepatitis, cholestasis, portal-vein thrombosis, Budd-Chiari syndrome, cholangitis, Wilson disease, and hemochromatosis. No increase in bile acids will be noted in patients with intestinal malabsorption. Metabolic hepatic disorders involving organic anions (eg, Gilbert disease, Crigler-Najjar syndrome, and Dubin-Johnson syndrome) do not cause abnormal serum bile acid concentrations.
The concentration of bile acids in serum is influenced by many different liver diseases due to the inability of the liver to efficiently extract circulating bile acids from portal blood.
In addition, bile acid levels are altered in several biochemical genetic conditions, such as peroxisomal biogenesis disorders (eg, Zellweger spectrum disorder) and disorders of bile acid synthesis (eg, D-bifunctional protein deficiency and alpha methyl-CoA racemase deficiency), due to the loss of specific enzymes important for bile acid metabolism.
This analysis includes a quantitative characterization of primary and secondary bile acids as well as 2 bile acid precursor species for the assessment of bile acid metabolism.
Reference Values
Chenodeoxycholic acid: ≤2.26 nmol/mL
Cholic acid: ≤2.74 nmol/mL
Deoxycholic acid: ≤2.84 nmol/mL
Dihydroxycholestanoic acid: ≤0.07 nmol/mL
Glycochenodeoxycholic acid: ≤5.14 nmol/mL
Glycocholic acid: ≤2.17 nmol/mL
Glycodeoxycholic acid: ≤3.88 nmol/mL
Glycohyodeoxycholic acid: ≤0.01 nmol/mL
Glycolithocholic acid: ≤0.11 nmol/mL
Glycoursodeoxycholic acid: ≤1.00 nmol/mL
Hyodeoxycholic acid: ≤0.12 nmol/mL
Lithocholic acid: ≤0.09 nmol/mL
Taurochenodeoxycholic acid: ≤0.80 nmol/mL
Taurocholic acid: ≤0.31 nmol/mL
Taurodeoxycholic acid: ≤0.78 nmol/mL
Taurohyodeoxycholic acid: ≤0.02 nmol/mL
Taurolithocholic acid: ≤0.04 nmol/mL
Tauroursodeoxycholic acid: ≤0.05 nmol/mL
Trihydroxycholestanoic acid: ≤1.73 nmol/mL
Ursodeoxycholic acid: ≤0.64 nmol/mL
Total bile acids: ≤19.00 nmol/mL
Day(s) Performed
Monday through FridayReport Available
3 to 5 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
82542